118 related articles for article (PubMed ID: 16358631)
1. [Diagnosis and treatment of hypertension. Individual aims, flexible control].
Zidek W; Paul M
MMW Fortschr Med; 2005 Nov; 147(46):35-6. PubMed ID: 16358631
[No Abstract] [Full Text] [Related]
2. [Comment on IOWiG report plan. A medical decision may not be replaced].
Vorstand der Deutschen Hochdruckliga E.V
MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705
[No Abstract] [Full Text] [Related]
3. [Treatment of hypertension. Between progress and cost control].
MMW Fortschr Med; 1999 Oct; 141(42):46. PubMed ID: 10912105
[No Abstract] [Full Text] [Related]
4. The value of antihypertensive drugs: a perspective on medical innovation.
Cutler DM; Long G; Berndt ER; Royer J; Fournier AA; Sasser A; Cremieux P
Health Aff (Millwood); 2007; 26(1):97-110. PubMed ID: 17211019
[TBL] [Abstract][Full Text] [Related]
5. [Treating hypertension only in case of high risk? Evidence-based therapy with cost control].
Trenkwalder P
MMW Fortschr Med; 2001 Feb; 143(7):45-6. PubMed ID: 11268751
[No Abstract] [Full Text] [Related]
6. [Innovation or pseudo-innovation: that is the question].
Unger T
Med Klin (Munich); 2006 Mar; 101(3):257-62. PubMed ID: 16648986
[No Abstract] [Full Text] [Related]
7. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
[No Abstract] [Full Text] [Related]
8. Hypertension treatment and control in Sub-saharan Africa. Figure of $1800 per life saved seems optimistic.
Burdon J
BMJ; 1998 Jul; 317(7150):76; author reply 77. PubMed ID: 9651283
[No Abstract] [Full Text] [Related]
9. [Pharmacoeconomic aspects of the treatment of essential hypertension].
Martynov AI; Giliarevskiĭ SR; Ostroumova OD; Nesterova MV; Mamaev VI
Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090
[No Abstract] [Full Text] [Related]
10. Cost of hypertension treatment and the price of health.
Menard J; Cornu P; Day M
J Hum Hypertens; 1992 Dec; 6(6):447-58. PubMed ID: 1296008
[No Abstract] [Full Text] [Related]
11. Cost containment and the treatment of hypertension.
Chillag SA
J S C Med Assoc; 1985 Feb; 81(2):61-4. PubMed ID: 3856703
[No Abstract] [Full Text] [Related]
12. Hypertension control: improved, but not enough!
Alderman MH
Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338
[No Abstract] [Full Text] [Related]
13. [Care in hypertension: guidelines and sources of error].
Simon G
Orv Hetil; 2005 May; 146(18):849-52. PubMed ID: 15926631
[No Abstract] [Full Text] [Related]
14. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
Keiding H; Hildebrandt P; Burke T; Carides GW
Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
[TBL] [Abstract][Full Text] [Related]
15. Economics of hypertension control.
Fletcher A
J Med Liban; 1994; 42(3):138-44. PubMed ID: 7629847
[No Abstract] [Full Text] [Related]
16. [Organizational committee shines with incompetence].
Aumiller J
MMW Fortschr Med; 2005 Dec; 147(51-52):59-60. PubMed ID: 16402712
[No Abstract] [Full Text] [Related]
17. Cost as a factor in the treatment of hypertension.
Dart RA
Contemp Intern Med; 1995 Feb; 7(2):10-4. PubMed ID: 10150334
[No Abstract] [Full Text] [Related]
18. Health economics and outcomes research with retrospective data.
Simons WR; Smith ME
Clin Ther; 1994; 16(6):1063-7; discussion 1036. PubMed ID: 7697685
[No Abstract] [Full Text] [Related]
19. Are there unintended consequences of step-therapy programs?
Cox ER; Seiz BJ
Am J Manag Care; 2009 Sep; 15(9):654, 656; author reply 656. PubMed ID: 19747030
[No Abstract] [Full Text] [Related]
20. [Clinical and pharmocoeconomic efficacy of the combined preparation tenoric in treatment of arterial hypertonia in middle-aged patients].
Ardashev VN; Danilov IuA; Filatova TG
Voen Med Zh; 2004 May; 325(5):31-4. PubMed ID: 15214182
[No Abstract] [Full Text] [Related]
[Next] [New Search]
